In addition, transforming growth factor‐beta (TGF‐β) secretion triggered by EGFR inhibition was also found to promote EMT and confer resistance to EGFR‐TKI treatment by activating the SAMD pathway in NSCLC.169. Here, EGFR is linked to non-small cell lung carcinoma.